Track sentiment, discussions and live quotes, post ideas and see what real traders are doing

Teslas quarterly results are drawing attention after a modest headline beat, while flat revenue and sharp declines in operating income and free cash flow have prompted debate over the strength of its core business. Some traders see potential SpaceX merger speculation and AI and robotaxi ambitions as support; others argue weak fundamentals and valuation concerns outweigh them, and no merger is confirmed.

Metas quarterly results and outlook are driving attention: strong advertising growth and forward revenue guidance fueled an after-hours rally, while a large legal charge weighed on reported earnings. Traders are divided over whether ad momentum justifies rising AI spending, which pressured cash flow and revived concerns about potential share issuance.

Lam Researchs quarterly results beat expectations, but shares are drawing attention after investors judged the next-quarter outlook insufficient following a strong sequential rebound. Traders are split between seeing a sell-the-news reaction amid high expectations and viewing the pullback as an overreaction, with some attributing slower near-term growth to customer fab-space constraints rather than weaker demand.

IBMs quarterly results are driving attention, with traders focusing on an earnings beat and a higher free-cash-flow outlook. The reaction is broadly positive, though flat consulting growth, weaker mainframe revenue and narrower gross margins are cited as offsets.

Renewed focus on AI data-center power demand, reinforced by Elon Musks comments that power and cooling infrastructure constrain AI expansion, is boosting interest in Bloom Energys fuel-cell opportunity. Traders are optimistic about the growth narrative and upcoming earnings, while others warn that high expectations and valuation leave room for a volatile reaction.

Concerns about slowing sales in Celsiuss core brand and weak Nielsen data are weighing on sentiment, despite traders pointing to Alani Nus growth as an offset. The debate also centers on managements execution and speculative Pepsi buyout talk, while bulls cite insider buying and valuation as reasons for optimism.

Capricors pending FDA decision on deramiocel for Duchenne muscular dystrophy is driving attention, with the review focused on an amended application emphasizing upper-limb function and a decision expected by November 22. Traders are split: bulls cite the HOPE-3 upper-limb data and added extension results, while bears remain concerned about the prior advisory committee vote and disputed trial analyses, fueling anxiety around the binary outcome and recent selling.

The sharp selloff is centered on traders discussion that the Navy has stopped further purchases of BlackSea Technologies GARC drone boats, raising concerns about the acquisitions value and managements diligence. Some see the hit as limited to one program, citing other defense opportunities and contract cure periods, while others view the lost business as a major setback.

Alibaba is under pressure alongside a broader selloff in Chinese technology shares, with traders pointing to the Hang Seng Tech Index falling below 4,000 and concerns about Chinas economy and limited stimulus rather than a clear company-specific catalyst. The decline has intensified debate between bearish traders calling BABA a value trap and buyers arguing the shares are oversold and may find support.

Helus Pharma is drawing attention ahead of the expected Phase 3 topline readout for HLP003, its investigational adjunctive treatment for major depressive disorder. Traders are split between optimism that Phase 2 results will carry through and concern about Phase 3 efficacy, alongside dilution risk and volatile trading.